ArticlePDF Available

Roald Dahl's contribution to neurosurgery: The Wade-Dahl-Till shunt

Authors:
LETTER TO THE EDITOR
Roald Dahls contribution to neurosurgery:
the Wade-Dahl-Till shunt
Dennis R. Buis &Ellen S. Mandl
Received: 28 September 2010 / Accepted: 29 September 2010 / Published online: 12 October 2010
#The Author(s) 2010. This article is published with open access at Springerlink.com
Although most physicians know Roald Dahl (19161990)
for the many wonderful novels and short stories he wrote,
due to a personal tragedy, he is also one of the inventors of
the modern ventricular catheters and shunt valves.
In 1960, while living in New York, his then 4-month-old
son Theo was hit by a New York taxi and suffered
traumatic brain injury with multiple skull fractures and
cerebral damage [2]. Theo survived, but developed second-
ary hydrocephalus. When his condition stabilized after
implantation of a ventriculo-atrial shunt, the Dahl family
moved back to the United Kingdom in January 1961 [2].
Back in the UK, Theo suffered from hydrocephalus due to
multiple shunt obstructions with debris clogging the
silicone slits of his Holter valve [2,5].
Dahl was determined to find a solution to this
problem. He contacted Stanley Wade, a toymaker who
specialized in making small hydraulic pumps that
supplied fuel to model aeroplane engines [2]. Meanwhile
Theos treatment was taken over by pediatric neurosur-
geon Kenneth Till at the Hospital for Sick Children at
Great Ormond Street in London, who invited both Dahl
and Wade in his operating room so they could see how the
shunts were used in clinical practice [2]. Together, they
designed a new introducer device for the ventricular
catheter and a valve for the treatment of hydrocephalus
in young children [3,4].
The inventors had observed that the valve became
obstructed by cerebral debris, which was introduced
through the slits of the ventricular catheter when the
catheter was inserted through the brain into the ventricles.
In order to prevent this, the openings (slits) of the
ventricular shunt should not come in contact with brain
during the initial placement [4]. A cannula (A) carrying a
hollow tube (B) or trocar (D) was inserted through a small
dural opening into the ventricles (Fig. 1). The plug of
braininside the hollow tube should be removed by the
release of cerebrospinal fluid (CSF) or by withdrawal of the
tube [4]. With the cannula in place, the hollow tube or
trocar was removed, and the ventricular catheter with a
stilette (C) was placed into the ventricles (Fig. 1). The
cannula was then removed over the ventricular drain with
the stilette holding the catheter in place. After removal of
the stilette, the ventricular shunt was in place without ever
having touched brain [4].
The commercially available valves had another problem:
they were expensive and often had plastic components that
could not be sterilized [3]. The WadeDahlTill (WDT) valve
was made of stainless steel, and patients were only charged
the costs to produce the valve [2,3]. Therefore, the WDT
valve cost less than a third of its predecessors [2,3].
In order to prevent obstruction of the valve, no non-
return slits, such as were used in the Holter valve [1], but a
moving steel disk was used, therefore CSF could be drained
through the widest possible surface. The valve consisted of
only six moving parts: a steel disk (E) placed in a four-
pronged cage (D) topped with a seat (B) placed in a
D. R. Buis
Neurosurgical Center Amsterdam, VU University Medical Center,
Amsterdam, The Netherlands
E. S. Mandl
Department of Neurosurgery, St. Elisabeth Hospital,
Tilburg, The Netherlands
D. R. Buis (*):E. S. Mandl (*)
Department of Neurosurgery, St. Elisabeth Ziekenhuis Tilburg,
P.O. Box 90151, 5000 LC Tilburg, The Netherlands
e-mail: drbuis@gmail.com
E. S. Mandl
e-mail: ellensmandl@gmail.com
Acta Neurochir (2011) 153:429430
DOI 10.1007/s00701-010-0834-z
cylinder (A) (Fig. 2). On the side of the seat, the steel disk
had a knife-edge round its rim to prevent backflow.
The valve was designed to shunt CSF into a cerebral
sinus and thus had an extremely low opening pressure of
0.20.5 cm water. When necessary, CSF could be pumped
out of the ventricles by applying digital pressure on the
valve through the scalp. The inventors explicitly mention
the risk of causing subdural hematomas when doing this in
older children with a closed fontanel [3].
The WDT valve was taken into production in 1962, and
the first patient was treated around June 1962. The WDT
valve was estimated to have been used in two to 3,000
children worldwide in the next couple of years, before it
became superseded by novel types of valve. Fortunately for
Roald Dahl, in 1962, Theos hydrocephalus turned into an
arrested state, and he never received the carefully designed
WDT shunt.
Conflicts of interest None.
Open Access This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
1. Drake JM, Sainte-Rose C (1995) History of cerebrospinal fluid
shunts. In: Drake JM, Sainte-Rose C (eds) The shunt book.
Blackwell Science, Cambridge, pp 312
2. Sturrock D (2010) A tornado of troubles. Storyteller. The life of
Roald Dahl. Harper Press, London, pp 356385
3. Till K (1964) A valve for the treatment of hydrocephalus. Lancet
283:202
4. Till K (1964) Introducer for intraventricular catheter used in
treatment of hydrocephalus. Lancet 1:202
5. Treglown J (1995) Punishment and pain, unhappiness and despair.
Roald Dahl: a biography. Harvest/HBJ Book, Orlando, pp 136157
Fig. 2 The WadeDahlTill valve: Anarrow exit, Bseat, Ccylinder,
Dfour-pronged cage, Esteeldisk(takenfromTill[4], with
permission). The bottom arrow represents the direction of flow
Fig. 1 Introducer system for intraventricular catheter placement. A
cannula, Bhollow tube, Crigid stilette, Dtrocar (taken from Till [4],
with permission)
430 Acta Neurochir (2011) 153:429430
ResearchGate has not been able to resolve any citations for this publication.
Article
✓ An important factor in making a recommendation for treatment of a patient with arteriovenous malformation (AVM) is to estimate the risk of surgery for that patient. A simple, broadly applicable grading system that is designed to predict the risk of morbidity and mortality attending the operative treatment of specific AVM's is proposed. The lesion is graded on the basis of size, pattern of venous drainage, and neurological eloquence of adjacent brain. All AVM's fall into one of six grades. Grade I malformations are small, superficial, and located in non-eloquent cortex; Grade V lesions are large, deep, and situated in neurologically critical areas; and Grade VI lesions are essentially inoperable AVM's. Retrospective application of this grading scheme to a series of surgically excised AVM's has demonstrated its correlation with the incidence of postoperative neurological complications. The application of a standardized grading scheme will enable a comparison of results between various clinical series and ...
Chapter
The prevalence of brain arteriovenous malformations (BAVMs) in a given population is difficult to estimate. It is believed that between 0.14% and 0.8% of the population may present with a BAVM in a given year (Garretson 1985;Jellinger 1986). These varying figures result from studies of disparate populations, ranging from the residents in a small community (Mohr 1984)to autopsy series (Jellinger 1986). Overall, however, the incidence of symptomatic BAVMs in adults appears to represent about one-tenth the frequency of intracranial arterial aneurysms. Various neurosurgical series comparing the relative incidence of symptomatic BAVMs to that of brain tumors also show considerable variability, with figures ranging from 0.59% to 7.9% (Yasargil 1987). This reflects different referral patterns and the introduction of more sensitive diagnostic tools.
Article
We investigate patient outcome, risk of hemorrhage, and factors affecting obliteration after LINAC-based radiosurgery (RS) for cerebral arteriovenous malformations (AVM) treated after partial embolization. This analysis is based on 50 patients treated after prior embolization. According to the Spetzler-Martin criteria the AVM classification was as follows: 9 patients, Grade I (18%); 19, Grade II (38%); 18, Grade III (36%); and 4, Grade IV (8%). Median RS-based AVM score was 1.41. Median single dose was 18 Gy/ 80% isodose (range, 15-22 Gy) and median AVM volume was 4.0 cc (range, 0.2-22.6 cc). In all, 34 patients (68%) experienced hemorrhage before RS. Median follow-up was 3.1 year (range, 8.5 months to 15 years). Actuarial complete obliteration rate was 67% after 3 years and 78% after 4 years. The complete obliteration rate was significantly higher in AVM <3 cm (92% vs. 60%, p < 0.01) and in AVM Spetzler-Martin Grade I/II (90% vs. 59%, p < 0,01). Intracranial hemorrhage after RS was seen in 6 patients (12%) after 8.5 months median. Annual bleeding risk was 7.9% after 1 year and 2.2% after 2 years. It was found that AVM diameter > or =3 cm (p < 0.006), AVM volume > or =4 cc (p < 0.01), AVM score > or =1.5 (p < 0.03), and single dose <18 Gy (p < 0.03) were associated with a significant higher bleeding risk. The rate of obliteration after RS in AVM treated after prior partial embolization depends on size as well as Spetzler-Martin grade. The risk of intracranial hemorrhage is not increased after RS and depends on AVM score, size, and volume, as well as on applied single dose.
Article
The reported efficacy of AVM radiosurgery--80-85% 2-year obliteration rate--is based exclusively on the results of follow-up arteriography in a small percentage of treated patients; it is therefore inaccurate. We examined the effect of incomplete follow-up on the results of AVM radiosurgery. We reviewed the results of AVM radiosurgery in 82 patients after a minimum of 24 months of follow-up. Patients were not preselected to undergo arteriography on the basis of any other imaging study. Data were analyzed using the Kaplan-Meier method and stratified by size of AVM. Results were compared with those obtained from the same data using the reporting techniques described in the literature. When data analysis was limited to patients who had follow-up arteriography, the 2-, 3-, and 4-year obliteration rates were 37%, 73%, and 84% after a minimum 24-month follow-up. Using Kaplan-Meier analysis the 2-, 3-, and 4-year obliteration rates were 32%, 55%, and 55% (95% CI = +/-18%), respectively. The 2-year obliteration rate was 43% for AVMs <30 mm in diameter and 16% for AVMs >30 mm in diameter, respectively. If data analysis is limited to the patients who undergo follow-up arteriography, the obliteration rate of AVM radiosurgery is overestimated. The actual 2-year obliteration rate if all data is considered is in the range of 40% rather than the commonly reported 80%. Therefore, treated patients are exposed to the risk of intracerebral hemorrhage for a longer period than previously appreciated. Compulsive long-term follow-up is required to document the true AVM obliteration rate after treatment by radiosurgery.
Article
The authors conducted a retrospective study to examine data on rates of obliteration of arteriovenous malformations (AVMs) with use of various combinations of treatment modalities based on Gamma Knife surgery (GKS). The authors believe that this study is the first to report on patients treated with embolization followed by staged GKS. The authors identified 150 patients who underwent GKS for treatment of AVMs between 1994 and 2004. In a retrospective study, 4 independent groups emerged based on the various combinations of treatment: 92 patients who underwent unstaged GKS, 28 patients who underwent embolization followed by unstaged GKS, 23 patients who underwent staged GKS, and 7 patients who underwent embolization followed by staged GKS. A minimum of 3 years of follow-up after the last GKS treatment was required for inclusion in the retrospective analysis. Angiograms, MR images, or CT scans at follow-up were required for calculating rates of obliteration of AVMs. Fifty-seven of 150 patients (38%) supplied angiograms, and overall obliteration was confirmed in 43 of these 57 patients (75.4%). An additional 37 patients had follow-up MR images or CT scans. The overall obliteration rate, including patients with follow-up angiograms and patients with follow-up MR images or CT scans, was 68 of 94 (72.3%). Patients who underwent unstaged GKS had a follow-up rate of 58.7% (54 of 92) and an obliteration rate of 75.9% (41 of 54). Patients who underwent embolization followed by unstaged GKS had a follow-up rate of 53.5% (15 of 28) and an obliteration rate of 60.0% (9 of 15). Patients who underwent staged GKS had a follow-up rate of 82.6% (19 of 23) and an obliteration rate of 73.7% (14 of 19). Patients who underwent embolization followed by staged GKS had a follow-up rate of 85.7% (6 of 7) and an obliteration rate of 66.7% (4 of 6). Gamma Knife surgery is an effective means of treating AVMs. Embolization prior to GKS may reduce AVM obliteration rates. Staged GKS is a promising method for obtaining high obliteration rates when treating larger AVMs in eloquent locations.
Article
Patients harboring brain arteriovenous malformations (bAVMs) are at a lifelong risk for hemorrhagic strokes, but the natural history is poorly understood. We examined the impact of demographic and angiographic features on the likelihood of future hemorrhage. A prospectively accrued database of bAVM patients maintained at the Toronto Western Hospital was analyzed; 678 consecutive, prospectively enrolled bAVM patients were followed for 1931.7 patient-years. The rate of hemorrhage over long-term follow-up was recorded. The impact of baseline clinical and radiographic features and partial treatment on time to hemorrhage were analyzed using survival analysis. Neurological outcome after hemorrhage was assessed using the Glasgow Outcome Score. Hemorrhage rates were 4.61% per year for the entire cohort (n=678), 7.48% per year for bAVMs with initial hemorrhagic presentation (n=258), 4.16% per year for initial seizure presentation (n=260), 3.99% per year for patients not harboring aneurysms (n=556), 6.93% per year for patients with associated aneurysms (n=122), and 5.42% per year for bAVMs with deep venous drainage (n=365). Hemorrhagic presentation was a significant independent predictor of future hemorrhage (HR, 2.15; P<0.01), whereas associated aneurysms (HR, 1.59; P=0.07) and deep venous drainage (HR, 1.59; P=0.07) showed a trend toward significance. Hemorrhage risk was unchanged in patients who underwent partial arteriovenous malformation embolization (n=211; HR, 0.875; P=0.32). Brain arteriovenous malformations presenting with hemorrhage, with deep venous drainage, or associated aneurysms have approximately 2-fold greater likelihood of a future hemorrhage. Partial treatment by embolization does not alter these risks. This natural history should be taken into account in the treatment strategy.